Cognitive ImpairmentPhase 2NCT03186638
Low-Dose Ibuprofen in Improving Cognitive Impairment in Patients With Cancer
A Phase 2 study testing Ibuprofen and Questionnaire Administration in people with Cognitive Impairment and Malignant Neoplasm, run by University of Rochester NCORP Research Base at 169 sites in United States.
Trial summary
This randomized phase II trial studies how well low-dose ibuprofen in improving cognitive impairment in patients with cancer. Anti-inflammatory agents, such as ibuprofen, may slow the decline of cognitive processes and diseases involving the brain. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Cognitive Impairment, Malignant Neoplasm
- What is being tested?
- Ibuprofen and Questionnaire Administration
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 87 participants
- Where
- 169 sitesUnited States
- Study dates
- 26 May 2017to 1 Jun 2022
- Phase
- Phase 2
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Have a diagnosis of cancer and have had surgery and are now receiving adjuvant or neoadjuvant chemotherapy or who have received chemotherapy within the last 6 months; chemotherapy with concurrent radiation therapy (RT) is allowed
- Answer YES to the question: "Have you noticed any problems in your memory, attention, concentration, multi-tasking or other cognitive functions?" any time after initiation of chemotherapy cycle 1
- NOTE: If a participant answers NO, they may be re-approached at a subsequent cycle
- Be able to swallow medication
- Be able to read English
- Have the ability to understand and to give written informed consent as assessed by the participant's primary care physician or medical oncologist
Who cannot join
- Have a confirmed brain tumor or brain metastases
- Be taking a regular daily dose of an NSAID NOTE: Daily doses of 81 mg aspirin are permitted and higher doses of an NSAID on an 'as needed' basis are permitted
- Be diagnosed with dementia or severe neurodegenerative disease
- Have a contraindication to NSAIDs at the oncologist's discretion (i.e., allergy, worsening of ongoing medical problem due to NSAID, very low platelet count from chemotherapy, full-dose anti-coagulation/high risk of bleeding, and uncontrolled conditions such as hypertension, asthma, or peptic ulcer disease)
- Have been hospitalized for treatment of a major psychiatric illness within the last five years
- Have a serum creatinine above 1.5 upper limit of normal (ULN) (collected within the past 4 weeks); ULN is per institutional definition
Show all 9Show fewer
- Concurrent administration of warfarin, full dose aspirin, clopidogrel, apixaban or other medications known to increase the risk of bleeding or to interfere with antiplatelet activities
- Be colorblind
- Have active substance abuse (e.g. alcohol, drugs) per self-report or medical record
Trial locations and contacts
169 sites in 1 country.
169 sites in 1 country
United States169 sites
Providence Regional Cancer System-Aberdeen
Aberdeen, Washington, 98520
Cancer Care Center at Island Hospital
Anacortes, Washington, 98221
Cancer Care of Western North Carolina
Asheville, North Carolina, 28801
Mission Hospital Inc-Memorial Campus
Asheville, North Carolina, 28801
Hope Women's Cancer Centers-Asheville
Asheville, North Carolina, 28816
Bronson Battle Creek
Battle Creek, Michigan, 49017
PeaceHealth Saint Joseph Medical Center
Bellingham, Washington, 98225
Saint Charles Health System
Bend, Oregon, 97701
Illinois CancerCare-Bloomington
Bloomington, Illinois, 61704
Saint Luke's Mountain States Tumor Institute
Boise, Idaho, 83712
Parkland Health Center-Bonne Terre
Bonne Terre, Missouri, 63628
Providence Saint Joseph Medical Center/Disney Family Cancer Center
Burbank, California, 91505
Fairview Ridges Hospital
Burnsville, Minnesota, 55337
Illinois CancerCare-Canton
Canton, Illinois, 61520
Saint Francis Medical Center
Cape Girardeau, Missouri, 63703
Southeast Cancer Center
Cape Girardeau, Missouri, 63703
Memorial Hospital of Carbondale
Carbondale, Illinois, 62902
Carson Tahoe Regional Medical Center
Carson City, Nevada, 89703
SIH Cancer Institute
Carterville, Illinois, 62918
Illinois CancerCare-Carthage
Carthage, Illinois, 62321
Centralia Oncology Clinic
Centralia, Illinois, 62801
Providence Regional Cancer System-Centralia
Centralia, Washington, 98531
Christiana Care Health System-Concord Health Center
Chadds Ford, Pennsylvania, 19317
Clackamas Radiation Oncology Center
Clackamas, Oregon, 97015
Providence Oncology and Hematology Care Southeast
Clackamas, Oregon, 97015
Greenville Health System Cancer Institute-Laurens
Clinton, South Carolina, 29325
Marietta Memorial Hospital
Columbus, Ohio, 43215
Mercy Hospital
Coon Rapids, Minnesota, 55433
Bay Area Hospital
Coos Bay, Oregon, 97420
Cancer Care Specialists of Illinois - Decatur
Decatur, Illinois, 62526
Decatur Memorial Hospital
Decatur, Illinois, 62526
Greenville Health System Cancer Institute-Easley
Easley, South Carolina, 29640
Fairview-Southdale Hospital
Edina, Minnesota, 55435
Swedish Medical Center-Edmonds
Edmonds, Washington, 98026
Crossroads Cancer Center
Effingham, Illinois, 62401
Illinois CancerCare-Eureka
Eureka, Illinois, 61530
Providence Regional Cancer Partnership
Everett, Washington, 98201
Unity Hospital
Fridley, Minnesota, 55432
Saint Luke's Mountain States Tumor Institute - Fruitland
Fruitland, Idaho, 83619
Illinois CancerCare-Galesburg
Galesburg, Illinois, 61401
Western Illinois Cancer Treatment Center
Galesburg, Illinois, 61401
Mercy Health Saint Mary's
Grand Rapids, Michigan, 49503
Spectrum Health at Butterworth Campus
Grand Rapids, Michigan, 49503
Greenville Health System Cancer Institute-Butternut
Greenville, South Carolina, 29605
Greenville Health System Cancer Institute-Faris
Greenville, South Carolina, 29605
Greenville Memorial Hospital
Greenville, South Carolina, 29605
Greenville Health System Cancer Institute-Eastside
Greenville, South Carolina, 29615
Greenville Health System Cancer Institute-Greer
Greer, South Carolina, 29650
Cancer and Blood Specialists-Henderson
Henderson, Nevada, 89052
Comprehensive Cancer Centers of Nevada - Henderson
Henderson, Nevada, 89052
Comprehensive Cancer Centers of Nevada-Horizon Ridge
Henderson, Nevada, 89052
Las Vegas Cancer Center-Henderson
Henderson, Nevada, 89052
OptumCare Cancer Care at Seven Hills
Henderson, Nevada, 89052
21st Century Oncology-Henderson
Henderson, Nevada, 89074
Comprehensive Cancer Centers of Nevada-Southeast Henderson
Henderson, Nevada, 89074
Swedish Cancer Institute-Issaquah
Issaquah, Washington, 98029
Capital Region Southwest Campus
Jefferson City, Missouri, 65109
Bronson Methodist Hospital
Kalamazoo, Michigan, 49007
West Michigan Cancer Center
Kalamazoo, Michigan, 49007
Borgess Medical Center
Kalamazoo, Michigan, 49048
Kadlec Clinic Hematology and Oncology
Kennewick, Washington, 99336
Illinois CancerCare-Kewanee Clinic
Kewanee, Illinois, 61443
Providence Regional Cancer System-Lacey
Lacey, Washington, 98503
Desert West Surgery
Las Vegas, Nevada, 89102
University Medical Center of Southern Nevada
Las Vegas, Nevada, 89102
Hope Cancer Care of Nevada
Las Vegas, Nevada, 89103
Cancer and Blood Specialists-Shadow
Las Vegas, Nevada, 89106
OptumCare Cancer Care at Oakey
Las Vegas, Nevada, 89106
21st Century Oncology
Las Vegas, Nevada, 89109
HealthCare Partners Medical Group Oncology/Hematology-Maryland Parkway
Las Vegas, Nevada, 89109
HealthCare Partners Medical Group Oncology/Hematology-San Martin
Las Vegas, Nevada, 89113
Radiation Oncology Centers of Nevada Southeast
Las Vegas, Nevada, 89119
Cancer Therapy and Integrative Medicine
Las Vegas, Nevada, 89121
21st Century Oncology-Vegas Tenaya
Las Vegas, Nevada, 89128
Ann M Wierman MD LTD
Las Vegas, Nevada, 89128
Cancer and Blood Specialists-Tenaya
Las Vegas, Nevada, 89128
Comprehensive Cancer Centers of Nevada - Northwest
Las Vegas, Nevada, 89128
HealthCare Partners Medical Group Oncology/Hematology-Tenaya
Las Vegas, Nevada, 89128
OptumCare Cancer Care at MountainView
Las Vegas, Nevada, 89128
Comprehensive Cancer Centers of Nevada-Summerlin
Las Vegas, Nevada, 89144
Summerlin Hospital Medical Center
Las Vegas, Nevada, 89144
Las Vegas Cancer Center-Medical Center
Las Vegas, Nevada, 89148-2405
21st Century Oncology-Fort Apache
Las Vegas, Nevada, 89148
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada, 89148
OptumCare Cancer Care at Fort Apache
Las Vegas, Nevada, 89148
HealthCare Partners Medical Group Oncology/Hematology-Centennial Hills
Las Vegas, Nevada, 89149
Comprehensive Cancer Centers of Nevada - Central Valley
Las Vegas, Nevada, 89169
University Cancer Center
Las Vegas, Nevada, 89169
Beebe Medical Center
Lewes, Delaware, 19958
PeaceHealth Saint John Medical Center
Longview, Washington, 98632
Illinois CancerCare-Macomb
Macomb, Illinois, 61455
Fairview Maple Grove Medical Center
Maple Grove, Minnesota, 55369
Minnesota Oncology Hematology PA-Maplewood
Maplewood, Minnesota, 55109
Saint John's Hospital - Healtheast
Maplewood, Minnesota, 55109
Saint Luke's Mountain States Tumor Institute - Meridian
Meridian, Idaho, 83642
Abbott-Northwestern Hospital
Minneapolis, Minnesota, 55407
Hennepin County Medical Center
Minneapolis, Minnesota, 55415
Health Partners Inc
Minneapolis, Minnesota, 55454
Monticello Cancer Center
Monticello, Minnesota, 55362
Mercy Health Mercy Campus
Muskegon, Michigan, 49444
Saint Luke's Mountain States Tumor Institute - Nampa
Nampa, Idaho, 83686
Cancer Center of Western Wisconsin
New Richmond, Wisconsin, 54017
New Ulm Medical Center
New Ulm, Minnesota, 56073
Delaware Clinical and Laboratory Physicians PA
Newark, Delaware, 19713
Helen F Graham Cancer Center
Newark, Delaware, 19713
Medical Oncology Hematology Consultants PA
Newark, Delaware, 19713
Regional Hematology and Oncology PA
Newark, Delaware, 19713
Christiana Care Health System-Christiana Hospital
Newark, Delaware, 19718
Providence Newberg Medical Center
Newberg, Oregon, 97132
Lakeland Hospital Niles
Niles, Michigan, 49120
Providence Willamette Falls Medical Center
Oregon City, Oregon, 97045
Illinois CancerCare-Ottawa Clinic
Ottawa, Illinois, 61350
Hope Cancer Care of Nevada-Pahrump
Pahrump, Nevada, 89048
Illinois CancerCare-Pekin
Pekin, Illinois, 61554
OSF Saint Francis Radiation Oncology at Pekin Cancer Treatment Center
Pekin, Illinois, 61554
Illinois CancerCare-Peoria
Peoria, Illinois, 61615
OSF Saint Francis Radiation Oncology at Peoria Cancer Center
Peoria, Illinois, 61615
Methodist Medical Center of Illinois
Peoria, Illinois, 61636
OSF Saint Francis Medical Center
Peoria, Illinois, 61637
Illinois CancerCare-Peru
Peru, Illinois, 61354
Valley Radiation Oncology
Peru, Illinois, 61354
Providence Portland Medical Center
Portland, Oregon, 97213
Providence Saint Vincent Medical Center
Portland, Oregon, 97225
Illinois CancerCare-Princeton
Princeton, Illinois, 61356
Spectrum Health Reed City Hospital
Reed City, Michigan, 49677
Beebe Health Campus
Rehoboth Beach, Delaware, 19971
Renown Regional Medical Center
Reno, Nevada, 89502
Saint Mary's Regional Medical Center
Reno, Nevada, 89503
Radiation Oncology Associates
Reno, Nevada, 89509
North Memorial Medical Health Center
Robbinsdale, Minnesota, 55422
Lakeland Medical Center Saint Joseph
Saint Joseph, Michigan, 49085
Marie Yeager Cancer Center
Saint Joseph, Michigan, 49085
Park Nicollet Clinic - Saint Louis Park
Saint Louis Park, Minnesota, 55416
Regions Hospital
Saint Paul, Minnesota, 55101
United Hospital
Saint Paul, Minnesota, 55102
Sainte Genevieve County Memorial Hospital
Sainte Genevieve, Missouri, 63670
Nanticoke Memorial Hospital
Seaford, Delaware, 19973
Pacific Gynecology Specialists
Seattle, Washington, 98104
Swedish Medical Center-Ballard Campus
Seattle, Washington, 98107
Kaiser Permanente Washington
Seattle, Washington, 98112
Swedish Medical Center-First Hill
Seattle, Washington, 98122-4307
Swedish Medical Center-Cherry Hill
Seattle, Washington, 98122-5711
Greenville Health System Cancer Institute-Seneca
Seneca, South Carolina, 29672
Saint Francis Regional Medical Center
Shakopee, Minnesota, 55379
Providence Regional Cancer System-Shelton
Shelton, Washington, 98584
Greenville Health System Cancer Institute-Spartanburg
Spartanburg, South Carolina, 29307
Rockwood Cancer Treatment Center-DHEC-Downtown
Spokane, Washington, 99204
Rockwood North Cancer Treatment Center
Spokane, Washington, 99218
Rockwood Clinic Cancer Treatment Center-Valley
Spokane Valley, Washington, 99216
Southern Illinois University School of Medicine
Springfield, Illinois, 62702
Springfield Clinic
Springfield, Illinois, 62702
Memorial Medical Center
Springfield, Illinois, 62781
Missouri Baptist Medical Center
St Louis, Missouri, 63131
Lakeview Hospital
Stillwater, Minnesota, 55082
Missouri Baptist Sullivan Hospital
Sullivan, Missouri, 63080
Missouri Baptist Outpatient Center-Sunset Hills
Sunset Hills, Missouri, 63127
Cancer Care Specialists of Illinois-Swansea
Swansea, Illinois, 62226
Southwest Illinois Health Services LLP
Swansea, Illinois, 62226
Munson Medical Center
Traverse City, Michigan, 49684
Saint Luke's Mountain States Tumor Institute-Twin Falls
Twin Falls, Idaho, 83301
PeaceHealth Southwest Medical Center
Vancouver, Washington, 98664
Ridgeview Medical Center
Waconia, Minnesota, 55387
Providence Saint Mary Regional Cancer Center
Walla Walla, Washington, 99362
Rice Memorial Hospital
Willmar, Minnesota, 56201
Christiana Care Health System-Wilmington Hospital
Wilmington, Delaware, 19801
Minnesota Oncology Hematology PA-Woodbury
Woodbury, Minnesota, 55125
Metro Health Hospital
Wyoming, Michigan, 49519
Fairview Lakes Medical Center
Wyoming, Minnesota, 55092
Providence Regional Cancer System-Yelm
Yelm, Washington, 98597
About this study
Official title: Phase II Study of Low-Dose Ibuprofen for Cognitive Problems in Patients With Cancer
This randomized phase II trial studies how well low-dose ibuprofen in improving cognitive impairment in patients with cancer. Anti-inflammatory agents, such as ibuprofen, may slow the decline of cognitive processes and diseases involving the brain.
Read the detailed description
PRIMARY OBJECTIVES:
- To provide preliminary data on the effect of ibuprofen on alleviating chemotherapy-related cognitive impairment (CRCI) in cancer patients receiving chemotherapy or who have received chemotherapy within the last 6 months compared to a placebo control, as assessed by the Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog).
OUTLINE: Patients are randomized into 1 of 2 arms.
ARM I: Patients receive ibuprofen orally (PO) twice daily (BID) for 6 weeks.
ARM II: Patients receive placebo PO BID for 6 weeks.
After completion of study, patients are followed up periodically.
- Conditions
- Cognitive Impairment, Malignant Neoplasm
- Being tested
- Ibuprofen, Placebo, Questionnaire Administration
- Medical subject headings
- Cognitive Dysfunction, Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
IbuprofenDrug
Also called (.+ -.)-p-Isobutylhydratropic acid, Advil, Motrin, p-Isobutylhydratropic acid
Given PO
PlaceboOther
Also called placebo therapy, PLCB, sham therapy
Given PO
Questionnaire AdministrationOther
Ancillary studies
| Study group | Role | What they receive |
|---|---|---|
| Arm I (ibuprofen) | Experimental | Patients receive ibuprofen PO BID for 6 weeks. Receives: Drug: Ibuprofen; Other: Questionnaire Administration |
| Arm II (placebo) | Placebo comparator | Patients receive placebo PO BID for 6 weeks. Receives: Other: Placebo; Other: Questionnaire Administration |
What is being measured
The primary outcome is the main question the study is designed to answer.
Effects of Ibuprofen on Alleviating Chemotherapy-related Cognitive Impairment
Will be assessed by the Functional Assessment of Cancer Therapy-Cognitive Function. Means, standard deviations, and 95% confidence intervals will be determined in order to estimate preliminary population variances and effect sizes. These statistical measures will be calculated by group for the Pre(Baseline) and Post(6 Weeks) measures of the Functional Assessment of Cancer Therapy-Cognitive Function scores as well as the change (post-pre) in the scores using the subjects that completed the study (complete case estimation). The complete case estimates will be compared to multiple imputation estimates based on all subjects that completed pre-intervention. An analysis of covariance will be run using Functional Assessment of Cancer Therapy-Cognitive Function post-intervention as the response. Higher scores indicate better function; range is 0 to 148.
Measured: Up to 41 days post-intervention
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Jun 2017
- Study start26 May 2017
- Primary completion30 Mar 2022
- Study completion1 Jun 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Cognitive ImpairmentStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 87 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Rochester NCORP Research Base
- Sponsor type
- University, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Responsible party
- Principal investigator, Michelle Janelsins, PhD, MPH, University of Rochester NCORP Research Base
- Investigators
- Michelle C Janelsins, Principal investigator, University of Rochester NCORP Research Base
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03186638
- Sponsor's protocol ID
- URCC16092
- Other IDs
- NCI-2017-00790, URCC16092, URCC-16092, URCC-16092, R21CA187500, UG1CA189961
- Status last verified
- Sep 2023
- First submitted
- 7 Jun 2017
- Last updated
- 25 Sep 2023
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 25 Sep 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Phase II Study of Low-Dose Ibuprofen for Cognitive Problems in Patients With Cancer
- ClinicalTrials.gov ID
- NCT03186638
- Acronym / sponsor ID
- URCC16092
- Conditions
- Cognitive Impairment, Malignant Neoplasm
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 87 participants (actual)
- Lead sponsor
- University of Rochester NCORP Research BaseUniversity, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Study start
- 26 May 2017 (actual)
- Primary completion
- 30 Mar 2022 (actual)
- Study completion
- 1 Jun 2022 (actual)
- First posted
- 14 Jun 2017 (actual)
- Results
- Posted 21 Apr 2023
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This randomized phase II trial studies how well low-dose ibuprofen in improving cognitive impairment in patients with cancer. Anti-inflammatory agents, such as ibuprofen, may slow the decline of cognitive processes and diseases involving the brain.
Detailed description
PRIMARY OBJECTIVES:
- To provide preliminary data on the effect of ibuprofen on alleviating chemotherapy-related cognitive impairment (CRCI) in cancer patients receiving chemotherapy or who have received chemotherapy within the last 6 months compared to a placebo control, as assessed by the Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog).
OUTLINE: Patients are randomized into 1 of 2 arms.
ARM I: Patients receive ibuprofen orally (PO) twice daily (BID) for 6 weeks.
ARM II: Patients receive placebo PO BID for 6 weeks.
After completion of study, patients are followed up periodically.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Arm I (ibuprofen) | Experimental | Drug: Ibuprofen, Other: Questionnaire AdministrationPatients receive ibuprofen PO BID for 6 weeks. |
| Arm II (placebo) | Placebo comparator | Other: Placebo, Other: Questionnaire AdministrationPatients receive placebo PO BID for 6 weeks. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Have a diagnosis of cancer and have had surgery and are now receiving adjuvant or neoadjuvant chemotherapy or who have received chemotherapy within the last 6 months; chemotherapy with concurrent radiation therapy (RT) is allowed
- Answer YES to the question: "Have you noticed any problems in your memory, attention, concentration, multi-tasking or other cognitive functions?" any time after initiation of chemotherapy cycle 1
- Be able to swallow medication
- Be able to read English
- Have the ability to understand and to give written informed consent as assessed by the participant's primary care physician or medical oncologist
Key exclusion criteria (9 listed)
- Have a confirmed brain tumor or brain metastases
- Be taking a regular daily dose of an NSAID NOTE: Daily doses of 81 mg aspirin are permitted and higher doses of an NSAID on an 'as needed' basis are permitted
- Be diagnosed with dementia or severe neurodegenerative disease
- Have a contraindication to NSAIDs at the oncologist's discretion (i.e., allergy, worsening of ongoing medical problem due to NSAID, very low platelet count from chemotherapy, full-dose anti-coagulation/high risk of bleeding, and uncontrolled conditions such as hypertension, asthma, or peptic ulcer disease)
- Have been hospitalized for treatment of a major psychiatric illness within the last five years
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| IbuprofenAlso: (.+ -.)-p-Isobutylhydratropic acid, Advil, Motrin, p-Isobutylhydratropic acidGiven PO | Drug | Arm I (ibuprofen) |
| PlaceboAlso: placebo therapy, PLCB, sham therapyGiven PO | Other | Arm II (placebo) |
| Questionnaire AdministrationAncillary studies | Other | Arm I (ibuprofen), Arm II (placebo) |
Primary outcome
Effects of Ibuprofen on Alleviating Chemotherapy-related Cognitive Impairment
Time frame: Up to 41 days post-intervention
Will be assessed by the Functional Assessment of Cancer Therapy-Cognitive Function. Means, standard deviations, and 95% confidence intervals will be determined in order to estimate preliminary population variances and effect sizes. These statistical measures will be calculated by group for the Pre(Baseline) and Post(6 Weeks) measures of the Functional Assessment of Cancer Therapy-Cognitive Function scores as well as the change (post-pre) in the scores using the subjects that completed the study (complete case estimation). The complete case estimates will be compared to multiple imputation estimates based on all subjects that completed pre-intervention. An analysis of covariance will be run using Functional Assessment of Cancer Therapy-Cognitive Function post-intervention as the response. Higher scores indicate better function; range is 0 to 148.
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Sep 2023.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Related trials for Cognitive Impairment
Recruiting
Telehealth-Adapted Compensatory Training and Intervention for Cognition
MCI, Mild Cognitive Impairment
Active, not recruitingPhase 2
Effect of Equol Supplementation on Arterial Stiffness and Cognition in Healthy Volunteers
Arterial Stiffness, White Matter Lesions
Recruiting
Neurobehavioral Changes Following Spaceflight Stressors
Stressor, Individual, Alcohol Impairment
RecruitingPhase 1
PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)
Alzheimer s Disease, Mild Cognitive Impairment
Recruiting
Treating Insomnia in Mild Cognitive Impairment
Mild Cognitive Impairment (MCI), Insomnia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Michelle C Janelsins principal investigator
University of Rochester NCORP Research Base
169 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Ibuprofen and Questionnaire Administration in people with Cognitive Impairment and Malignant Neoplasm, run by University of Rochester NCORP Research Base at 169 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 25 Sep 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 169 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 21 Apr 2023). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Effects of Ibuprofen on Alleviating Chemotherapy-related Cognitive Impairment (time frame: Up to 41 days post-intervention). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Sep 2023.